(Merged in 2005)
|Headquarters||2-5-1, Nihonbashi-Honcho, Chūō-ku, Tokyo 103-8411, Japan|
(President and CEO)
|Revenue||US$11,060,000,000 (FY 2013)|
|Profit||US$1,280,000,000 (¥1,139,000,000,000) (FY 2013)|
|Total assets||$14.86 billion (2016)|
Number of employees
|Footnotes / references
Astellas Pharma Inc. (アステラス製薬株式会社 Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社 Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 Fujisawa Yakuhin Kōgyō Kabushiki-gaisha).
Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943. Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942. Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards.
Recent times and mergers
Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D center in Deerfield, Illinois. Yamanouchi's R&D center in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991. Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005. At least some of its older products continue to be distributed under the original brand, ostensibly due to high brand-name recognition. Astellas had a collaboration agreement with CoMentis from 2008 to 2014 focused on development of beta-secretase inhibitor therapeutics for Alzheimer's disease.
On June 9, 2010, Astellas acquired OSI Pharmaceuticals for $4.0 billion. In December 2014, Astellas expanded its 18-month-old collaboration with Cytokinetics, focusing on the R&D and commercialisation of skeletal muscle activators. The companies announced they will advance the development of CK-2127107 (a fast skeletal troponin activator) into Phase II clinical trials for the treatment of spinal muscular atrophy and possibly other neuromuscular conditions. The companies have extended their R&D program focusing on the discovery of additional skeletal sarcomere activators through into 2016. The collaboration is expected to generate more than $600 million for Cytokinetics as well as $75 million in milestone payments. In November 2015 the company announced its move to acquire Ocata Therapeutics (formerly Advanced Cell Technology) for $379 million. As of January 14, 2016, Astellas has not been able to acquire a majority of Ocata's common stock, which is necessary to complete the acquisition. The first deadline in the acquisition was November 17, 2015, and due to Astellas' failure to acquire a majority of Ocata's common stock, the deadline was extended to January 21, 2016. Many long-term stockholders have vowed to fight this acquisition by every legal means available to them, because they claim that the Astellas offer represents a huge discount - not a premium - to what they say is Ocata's true value. The deal was finally completed in February 2016.  Later in November 2015 the company announce it would sell its dermatology business to LEO Pharma for $725 million. In October 2016 Astellas announced it would acquire Ganymed Pharmaceuticals for $1.4 billion
In April 2017, the company announced it would acquire Belgium-based drug discovery firm Ogeda for up to a total €800 million, strengthening its late-stage pipeline with Ogeda's GPCR-targeting drug candidate, fezolinetant.
In 2016, the Association of the British Pharmaceutical Industry gave Astella a year-long suspension, after complaints it had "purposely misled the PMCPA." Audits afterwards found that Astella was not adequately overseeing and training nurses, and had failed to provide complete prescribing information for several medicines. The company was suspended for a second year, and threatened with permanent expulsion in June 2017 for breaches of guidelines of the UK’s pharmaceutical industry trade body.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.
Some of the key products produced by Astellas include:
- Prograf (tacrolimus) - Prevention of post-transplant organ rejection
- Protopic (tacrolimus ointment) - Atopic dermatitis (eczema)
- Amevive (alefacept) - Plaque psoriasis
- VESIcare (solifenacin succinate) - Overactive bladder (OAB) marketed with GlaxoSmithKline
- Myrbetriq (mirabegron) - Overactive bladder (OAB) US only marketed by Pfizer Outside of US
- Flomax (tamsulosin hydrochloride) - Benign prostatic hyperplasia (BPH)
- Adenocard (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
- Adenoscan (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
- Lexiscan (regadenoson injection) - Pharmacologic stress agent for myocardial perfusion scan
- Vaprisol (conivaptan) - Hyponatremia
- AmBisome (amphotericin B) - Anti-fungal
- Cresemba (isavuconazole) - Anti-fungal
- Mycamine (micafungin sodium) - Anti-fungal
- Symoron (methadone HCL) - narcotics misuse cessation
- Tarceva (erlotinib) - Non-small cell lung cancer and pancreatic cancer
- Xtandi (enzalutamide) - Prostate cancer
The company's headquarters are in Tokyo, with research centers in Tsukuba and Osaka. Clinical development is centered in Northbrook, Illinois and Leiden, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people. The United States subsidiary of Astellas is Astellas US LLC.
The company's advertising slogans are:
- English: Leading Light for Life
- Japanese: Ashita wa kaerareru. (明日は変えられる。 Changing Tomorrow.)
- "Corporate Profile". Astellas Pharma. Retrieved September 9, 2014.
- "Annual Report 2014" (PDF). Astellas Pharma. Retrieved September 9, 2014.
- "Astellas Pharma Snapshot". Bloomberg Businessweek. Retrieved January 25, 2015.
- "Yamanouchi Pimafucin (natamycin) product line manufactured at least up to 11/2007"
- Staff (November 15, 2014). "Astellas Ends Alzehimer's Collaboration with CoMentis". Discovery & Development. Gen. Eng. Biotechnol. News (paper). 34 (20). p. 14.
- Megaw, Nicholas (June 23, 2017). "Drugmaker Astellas sanctioned for 'shocking' patient safety failures". Financial Times. United Kingdom. Retrieved June 23, 2017.
- Slatko, Joshua (December 2013). "BMS changes senior management team". People on the Move: Pharma. Med Ad News. p. 27.
- "Corporate Philosophy of Astellas Pharma". Astellas Pharma. Retrieved September 9, 2014.
- Official website—(in English)
|Wikimedia Commons has media related to Astellas Pharma.|